Trichlormethiazide - Generic Drug Details

What are the generic drug sources for trichlormethiazide and what is the scope of patent protection?

Trichlormethiazide is the generic ingredient in five branded drugs marketed by Sanofi Aventis Us, Schering, Lannett, Mast Mm, Chartwell Rx, Impax Labs, Par Pharm, Sandoz, and Watson Labs, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for trichlormethiazide.

Summary for trichlormethiazide

US Patents:	0
Tradenames:	5
Applicants:	9
NDAs:	15
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	84
DailyMed Link:	trichlormethiazide at DailyMed

Medical Subject Heading (MeSH) Categories for trichlormethiazide

Antihypertensive Agents

Diuretics

Sodium Chloride Symporter Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for trichlormethiazide

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

US Patents and Regulatory Information for trichlormethiazide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mast Mm	TRICHLORMAS	trichlormethiazide	TABLET;ORAL	086259-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	TRICHLORMETHIAZIDE	trichlormethiazide	TABLET;ORAL	083462-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	TRICHLORMETHIAZIDE	trichlormethiazide	TABLET;ORAL	083847-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Schering	NAQUA	trichlormethiazide	TABLET;ORAL	012265-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	TRICHLORMETHIAZIDE	trichlormethiazide	TABLET;ORAL	086171-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Schering	NAQUA	trichlormethiazide	TABLET;ORAL	012265-001	Approved Prior to Jan 1, 1982		DISCN	No	No

TRICHLORMETHIAZIDE: MARKET DYNAMICS AND FINANCIAL TRAJECTORY

Last updated: February 19, 2026

What is the current market landscape for Trichlormethiazide?

Trichlormethiazide is a thiazide diuretic used primarily for the management of hypertension and edema associated with congestive heart failure, hepatic cirrhosis, and renal dysfunction. Its market presence is characterized by its established efficacy, long history of use, and position as a foundational therapy in certain therapeutic areas. The drug is available as a generic medication, contributing to its cost-effectiveness and widespread accessibility.

The global market for antihypertensive drugs is substantial, driven by the increasing prevalence of cardiovascular diseases and the aging global population. Within this broad market, thiazide diuretics, including trichlormethiazide, represent a significant segment due to their established safety profiles and low cost. However, the market is also characterized by intense competition from newer classes of antihypertensives, such as angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers, which often offer improved efficacy or reduced side effect profiles for specific patient populations [1].

The competitive landscape for trichlormethiazide is primarily comprised of generic manufacturers. The patent exclusivity for the original drug has long expired, leading to a fragmented market with multiple suppliers. This genericization has resulted in significant price erosion, with the cost of treatment being substantially lower compared to branded or newer patented medications. Consequently, the revenue generated by trichlormethiazide is largely driven by volume rather than high per-unit pricing [2].

Geographically, the demand for trichlormethiazide is influenced by healthcare infrastructure, prevalence of hypertension, and prescription patterns. Developed markets, while having access to a wider array of advanced treatments, continue to utilize thiazide diuretics as first-line or adjunctive therapy due to their cost-effectiveness. Emerging markets, where cost is a more significant factor, often rely more heavily on generic medications like trichlormethiazide for managing chronic conditions such as hypertension [3]. Regulatory approvals and pricing policies within individual countries also play a critical role in shaping market access and penetration.

What are the key therapeutic indications and clinical utility?

Trichlormethiazide's primary clinical utility is as a diuretic and antihypertensive agent. Its mechanism of action involves inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the nephron. This action leads to increased excretion of sodium, chloride, and water, thereby reducing extracellular fluid volume and blood pressure.

The principal indications for trichlormethiazide include:

• Hypertension: It is used alone or in combination with other antihypertensive agents to lower elevated blood pressure. Its efficacy in reducing systolic and diastolic blood pressure has been well-documented in numerous clinical studies [1].
• Edema: It is prescribed to manage fluid retention (edema) associated with various conditions, including:
  • Congestive Heart Failure: By reducing fluid overload, it alleviates symptoms like shortness of breath and swelling.
  • Hepatic Cirrhosis: It helps manage ascites and peripheral edema in patients with liver disease.
  • Renal Dysfunction: It can be used to improve urine output and manage fluid balance in patients with certain kidney disorders.

The clinical utility of trichlormethiazide is supported by a long history of clinical experience. It is often considered a foundational therapy due to its predictable pharmacological profile and its role in established treatment guidelines. For hypertension, it is frequently recommended as a first-line agent, particularly in certain patient demographics, due to its efficacy and favorable cost-benefit ratio [4]. In combination therapy, it can potentiate the effects of other antihypertensive drugs, allowing for better blood pressure control while potentially reducing the required doses of individual agents.

The availability of fixed-dose combination products that include trichlormethiazide with other antihypertensives, such as ACE inhibitors or ARBs, further enhances its clinical utility by simplifying treatment regimens and improving patient adherence [2]. These combinations are designed to target different physiological pathways involved in blood pressure regulation, offering synergistic effects.

Despite its established role, the selection of trichlormethiazide in clinical practice is influenced by patient-specific factors, including comorbidities, electrolyte status, and potential drug interactions. Monitoring for side effects, such as hypokalemia, hyponatremia, and hyperglycemia, is a standard part of its clinical management.

What is the intellectual property (IP) landscape and patent status?

The intellectual property landscape for trichlormethiazide is characterized by the absence of active patent protection for the molecule itself. Trichlormethiazide was first introduced to the market several decades ago, and its original composition of matter patents have long expired. This has paved the way for widespread generic manufacturing and distribution.

Key aspects of the IP landscape include:

• Expired Composition of Matter Patents: The foundational patents covering the chemical structure and synthesis of trichlormethiazide are no longer in force. This means that any pharmaceutical company can legally manufacture and sell trichlormethiazide, provided they meet regulatory requirements for quality and safety.
• Absence of New Drug Applications (NDAs) with Exclusivity: There are no active NDAs for trichlormethiazide that would grant market exclusivity for a defined period. This contrasts with newer drugs that benefit from regulatory exclusivities tied to their approval.
• Potential for Process Patents: While the molecule itself is off-patent, there might be dormant or expired patents related to specific manufacturing processes or novel formulations of trichlormethiazide. However, the existence or impact of such patents on the current generic market is likely minimal, as common manufacturing methods are well-established and widely adopted.
• No Data Exclusivity: Unlike patented drugs, generic versions of trichlormethiazide do not benefit from data exclusivity periods, which protect the innovator's clinical trial data from being used by generic competitors for a certain duration.
• Fixed-Dose Combinations: While trichlormethiazide is off-patent, some fixed-dose combinations incorporating trichlormethiazide with other active pharmaceutical ingredients might have had their own patent protection. However, many of these combinations also have older formulations that are now off-patent or have been superseded by newer combinations with different patent protection.

The lack of active IP protection for trichlormethiazide directly contributes to its status as a commodity drug within the pharmaceutical market. The market is driven by manufacturing efficiency, cost of goods, and distribution channels, rather than proprietary innovation. Companies seeking to enter or compete in this market focus on optimizing their production processes to achieve the lowest possible cost per unit, thereby competing on price [2].

The generic nature of trichlormethiazide means that R&D investment in new patentable innovations directly related to trichlormethiazide itself is unlikely. Instead, innovation might occur in the development of novel drug delivery systems or combination therapies where trichlormethiazide is one component, though such developments would likely be tied to the patentability of the novel aspects rather than trichlormethiazide.

What is the financial trajectory and market size?

The financial trajectory of trichlormethiazide is characterized by a mature, highly competitive, and price-sensitive market. As a widely available generic medication, its revenue generation is primarily driven by volume sales rather than significant price increases.

Market Size and Revenue:

The precise global market size for trichlormethiazide as a standalone product is difficult to isolate, as it is often captured within broader categories such as "diuretics" or "antihypertensives." However, industry reports suggest that the global diuretic market, of which thiazides are a significant part, is valued in the billions of dollars annually. Within this, trichlormethiazide contributes a portion driven by its established usage.

Key financial characteristics include:

• Low Per-Unit Pricing: Due to generic competition, the average selling price for trichlormethiazide is very low. This is a direct consequence of multiple manufacturers producing the same active pharmaceutical ingredient, leading to commoditization.
• Volume-Driven Revenue: Despite low unit prices, the sustained demand for trichlormethiazide, particularly in emerging markets and as a cost-effective option in developed markets, ensures consistent volume sales. This volume underpins the revenue generated by manufacturers.
• Stable but Slow Growth: The market for trichlormethiazide exhibits stable demand. Growth is likely to be slow and primarily influenced by demographic factors (aging populations, increasing prevalence of hypertension) and healthcare access in developing economies, rather than by new indications or significant market expansion driven by innovation [3].
• Competition on Cost: The primary competitive lever for manufacturers is cost of production. Companies with efficient supply chains and optimized manufacturing processes are best positioned to maintain market share.
• Impact of Combination Therapies: A significant portion of trichlormethiazide's utilization is within fixed-dose combination products. The financial performance of these combinations contributes to the overall market presence of trichlormethiazide, though the revenue for these products is attributed to the combined entities.
• Reimbursement Policies: Reimbursement policies in different countries significantly influence prescription patterns and, consequently, sales volumes. Generic drugs like trichlormethiazide are generally favored by cost-containment measures in healthcare systems [4].

The financial trajectory suggests a steady-state market with limited potential for dramatic growth. Manufacturers are likely to focus on maintaining operational efficiency and optimizing supply chains to ensure profitability. Investment in new product development related to trichlormethiazide itself is minimal, with focus shifting towards other therapeutic areas or more innovative drug classes. Companies that continue to profit from trichlormethiazide do so through large-scale manufacturing and efficient distribution networks.

What are the competitive pressures and market threats?

Trichlormethiazide faces significant competitive pressures and market threats stemming from its generic status, the evolution of treatment guidelines, and the development of newer pharmacological agents.

Key Competitive Pressures:

• Intense Generic Competition: The market is saturated with generic manufacturers. This leads to a constant downward pressure on prices, limiting profitability per unit. Competition is primarily based on cost, reliability of supply, and established relationships with distributors and healthcare providers [2].
• Availability of Alternative Diuretics: While trichlormethiazide is a thiazide diuretic, it competes with other thiazides (e.g., hydrochlorothiazide, chlorthalidone) and thiazide-like diuretics. The choice between these agents often depends on physician preference, specific patient responses, and availability/cost. Hydrochlorothiazide, in particular, is a widely used and often interchangeable alternative.
• Advancement of Newer Antihypertensive Classes: The development and widespread adoption of newer classes of antihypertensive medications have diminished the exclusive dominance of thiazide diuretics. ACE inhibitors, ARBs, calcium channel blockers, and beta-blockers are often preferred as first-line agents for specific patient profiles due to their efficacy in managing comorbidities (e.g., diabetes, renal disease) and potentially fewer side effects in certain individuals [1, 4].
• Evolution of Treatment Guidelines: Clinical guidelines for hypertension management are continuously updated based on new research. While thiazide diuretics often remain recommended, their position as the sole first-line option may be challenged by other drug classes in specific patient populations or as part of a multi-drug regimen [4].
• Fixed-Dose Combinations: The market is increasingly moving towards fixed-dose combination therapies for chronic conditions like hypertension to improve patient adherence. While trichlormethiazide is part of some older combinations, newer, often patented, combination products may offer more comprehensive therapeutic benefits and gain market preference.
• Healthcare Cost Containment Measures: Governments and healthcare payers worldwide are implementing cost-containment strategies. These measures often favor the use of generics and can lead to preferred drug lists that may prioritize certain generic classes over others based on cost-effectiveness data.

Market Threats:

• Price Erosion: Continuous price erosion due to generic competition is a persistent threat, making it challenging for manufacturers to maintain healthy profit margins.
• Withdrawal of Products: If a manufacturer faces production issues, supply chain disruptions, or regulatory non-compliance, it could lead to temporary or permanent withdrawal of their product, impacting overall market supply but also potentially benefiting competitors.
• Emergence of Novel Therapies with Superior Efficacy or Safety: The discovery and approval of entirely new classes of drugs that offer significantly improved efficacy, safety, or convenience for hypertension and edema management could eventually displace older, established treatments like trichlormethiazide.
• Increased Emphasis on Personalized Medicine: As the field of personalized medicine advances, treatment decisions may increasingly be guided by genetic markers or other biomarkers, potentially leading to more tailored therapeutic choices that might not always include generic thiazide diuretics.

The long-term market position of trichlormethiazide will likely depend on its continued cost-effectiveness, its role in established treatment protocols, and its utility in fixed-dose combinations. Manufacturers must focus on operational efficiency and robust supply chain management to navigate these competitive pressures.

Key Takeaways

• Trichlormethiazide is a mature generic diuretic and antihypertensive drug with an established therapeutic profile.
• Its market is characterized by intense competition among generic manufacturers, leading to low per-unit pricing and volume-driven revenue.
• The drug lacks active patent protection, meaning its IP landscape is characterized by expired composition of matter patents.
• The financial trajectory is stable but slow-growing, driven by sustained demand and cost-effectiveness, particularly in emerging markets.
• Competitive pressures include price erosion, availability of alternative diuretics, and the ascendancy of newer antihypertensive drug classes and fixed-dose combinations.

Frequently Asked Questions

1. What is the primary driver of trichlormethiazide's continued market presence? Its primary driver is its established efficacy, long history of safe use, and significant cost-effectiveness as a generic medication, making it a valuable option for managing hypertension and edema, especially in price-sensitive markets.

2. Are there any ongoing clinical trials evaluating new indications for trichlormethiazide? Due to its mature status and generic nature, there are generally no significant ongoing clinical trials aimed at discovering new therapeutic indications for trichlormethiazide itself. Research typically focuses on newer, patented drug entities.

3. How does trichlormethiazide compare in cost to other thiazide diuretics like hydrochlorothiazide? Trichlormethiazide is generally priced comparably to other widely available generic thiazide diuretics, including hydrochlorothiazide, with slight variations depending on the manufacturer and market.

4. What is the typical market share of trichlormethiazide within the broader diuretic drug market? Precise market share data for trichlormethiazide as a standalone entity is difficult to ascertain, but it represents a segment within the larger thiazide diuretic market, which itself is a substantial part of the overall global diuretic and antihypertensive drug markets.

5. Can new patents be filed for trichlormethiazide, such as for novel delivery systems? While patents for the composition of matter of trichlormethiazide have expired, patents could potentially be filed for novel formulations, drug delivery systems, or specific combination therapies involving trichlormethiazide that offer a new and inventive approach. However, the commercial viability of such patents would depend on the significant improvement offered over existing treatments.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). Prescribing Information for Trichlormethiazide. Retrieved from FDA.gov (Note: This is a representative link to an example of prescribing information; specific current versions may vary).

[2] Global Generic Drugs Market Analysis. (2023). Fortune Business Insights. (Note: Specific reports are subscription-based; this indicates the type of source).

[3] World Health Organization. (2023). Cardiovascular diseases (CVDs): Key facts. Retrieved from WHO.int (Note: General prevalence data informs market drivers).

[4] National Institute for Health and Care Excellence. (2016). Hypertension in adults: diagnosis and management (NG133). Retrieved from NICE.org.uk (Note: Clinical guidelines influence drug selection and market dynamics).